The significant EPS miss and low cash balance raise near-term liquidity concerns, especially given the recent $50M ATM filing; monitor upcoming financing activity and clinical milestone timing for potential dilution risk.
Price Chart
Executive Summary
TuHURA Biosciences reported full-year 2025 financial results with no revenue and a net loss significantly worse than consensus, despite R&D and G&A expense growth. The company highlighted clinical progress and a $10.5M Kineta acquisition, but ended 2025 with only $3.6M cash, raising concerns about runway. This follows a recent $50M ATM offering, suggesting ongoing capital needs.
Key Financial Metrics
Key Facts
- Reported EPS of $-0.17 for FY 2025, missing consensus of $-0.11 by 54.5%
- No revenue reported for the period; company is pre-revenue
- R&D expenses increased to $20.5M from $13.3M in 2024; G&A rose to $7.6M from $3.9M
- Cash and equivalents were $3.6M at year-end, with $7.5M raised in Q1 2026
- Recent $50M ATM offering filed 13 days prior signals continued capital needs
Financial Impact
Net loss widened significantly year-over-year with no revenue, cash burn increased to $27.7M from $14.7M
Risk Factors
- Insufficient cash runway without additional financing
- High cash burn rate from increased R&D and G&A
- Dilution risk from the $50M ATM offering
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-135766 |
| Document: hura-ex99_1.htm | 0001193125-26-135766 |
| Document: 0001193125-26-135766-index-headers.html | 0001193125-26-135766 |
| Document: 0001193125-26-135766-index.html | 0001193125-26-135766 |
| Document: 0001193125-26-135766.txt | 0001193125-26-135766 |
| 8-K Data (Synthetic) | 0001193125-26-135766 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $1.78 | awaiting T+60 | — | $2.05 (+14.89%) |
Sep 24, 2026 4w ago | 8-K | $2.10 | awaiting T+60 | — | $2.05 (−2.62%) |
Sep 17, 2026 5w ago | 8-K | $2.10 | awaiting T+60 | — | $2.05 (−2.62%) |
Sep 16, 2026 5w ago | 8-K | $2.09 | awaiting T+60 | — | $2.05 (−2.15%) |
Sep 4, 2026 7w ago | 8-K | $2.12 | awaiting T+60 | — | $2.05 (−3.54%) |
Aug 19, 2026 9w ago | 8-K | $2.22 | awaiting T+60 | — | $2.05 (−7.88%) |
Aug 14, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.05 (−17.21%) |
Aug 14, 2026 10w ago | Press Release | $2.47 | awaiting T+60 | — | $2.05 (−17.21%) |
Aug 13, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.05 (−17.21%) |
Jul 29, 2026 12w ago | 8-K | $2.17 $2.18 | ▲ +0.46% | ▼ −2.00% | $2.05 (−5.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers